HAMP and hepatocellular carcinoma: Conversely, epigallocatenin3-gallate and myricetin led to a decrease in hepcidin levels in human and mouse hepatocytes [97] and in human hepatocellular carcinoma cells, in human embryonic kidney cells and in mice treated with LPS, respectively [98].